However, the presence of EIC (OR = 2.77, 95% CI: 1.80–4.27, P <0.001), LVI (OR = 1.64, 95% CI: 1.06–2.55, P = 0.026), pN stage (N1 vs. N0: OR = 1.56, 95% CI: 1.08–2.25, P = 0.018; N3 vs. N0: OR = 6.15, 95% CI: 2.92–12.98, P <0.001), histological subtype (presence of ductal carcinoma in situ (DCIS) component vs. IDC: OR = 2.42, 95% CI: 1.50–3.90, P <0.001) and BC subtype (luminal B vs. luminal A: OR = 2.03, 95% CI: 1.34–3.08, P = 0.001; HER-2 vs. luminal A: OR = 3.45, 95% CI: 2.11–5.63, P <0.001, Table 3) had a statistically significant correlation with positive CMs. The gene discussed is ERBB2; the disease is ductal breast carcinoma in situ.